Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...

Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

NEW YORK (Reuters) - Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty ...

The global topical applicator market is projected to grow from USD 443.3 million in 2024 to an impressive USD 662.5 million ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

Shares of consumer-products company Kenvue Inc. rose the most in more than two months after activist investor Starboard Value took a stake in the Tylenol maker with an eye toward making changes to ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...

Some of the steam is coming out of Wall Street’s record-breaking rally, as U.S. stocks edge back from their all-time highs.

Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.